Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial

Annals of Oncology ◽

10.1093/annonc/mdw331.03 ◽

2016 ◽

Vol 27 ◽

pp. iv2

Author(s):

M. Tiseo ◽

L. Boni ◽

F. Ambrosio ◽

A. Camerini ◽

E. Baldini ◽

...

Keyword(s):

Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Extensive Stage ◽

First Line Treatment

Download Full-text

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.8513 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 8513-8513

Author(s):

Marcello Tiseo ◽

Luca Boni ◽

Francesca Ambrosio ◽

Andrea Camerini ◽

Editta Baldini ◽

...

Keyword(s):

Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Extensive Stage ◽

First Line Treatment

Download Full-text

Italian Multicenter Phase III Randomized Study of Cisplatin–Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.09.001 ◽

2015 ◽

Vol 16 (1) ◽

pp. 67-70 ◽

Cited By ~ 6

Author(s):

Marcello Tiseo ◽

Luca Boni ◽

Francesca Ambrosio ◽

Andrea Camerini ◽

Maria Giuseppa Vitale ◽

...

Keyword(s):

Randomized Study ◽

Small Cell ◽

Protocol Design ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Extensive Stage ◽

First Line Treatment

Download Full-text

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.479 ◽

2021 ◽

Vol 32 (1) ◽

pp. 85-96 ◽

Cited By ~ 1

Author(s):

M. Shi ◽

A. Gu ◽

H. Tu ◽

C. Huang ◽

H. Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

P2-159: Phase III randomized study of oral vinorelbine (oV) and gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): A preliminary report

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283817.86250.51 ◽

2007 ◽

Vol 2 (8) ◽

pp. S632 ◽

Cited By ~ 1

Author(s):

S Agelaki ◽

N Androulakis ◽

A Agelidou ◽

M Agelidou ◽

A Kotsakis ◽

...

Keyword(s):

Lung Cancer ◽

Preliminary Report ◽

Randomized Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Oral Vinorelbine ◽

First Line Treatment

Download Full-text

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3-3 ◽

Cited By ~ 70

Author(s):

R. Pirker ◽

A. Szczesna ◽

J. von Pawel ◽

M. Krzakowski ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

Reviews on Recent Clinical Trials ◽

10.2174/15748871112079990040 ◽

2013 ◽

Vol 8 (1) ◽

pp. 23-28 ◽

Cited By ~ 4

Author(s):

Cesare Gridelli ◽

Paolo Maione ◽

Antonio Rossi

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283155.03863.e7 ◽

2007 ◽

Vol 2 (8) ◽

pp. S340-S341 ◽

Cited By ~ 58

Author(s):

Thomas J. Lynch ◽

Taral Patel ◽

Luke Dreisbach ◽

Michael McCleod ◽

William J. Heim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdr030 ◽

2012 ◽

Vol 23 (1) ◽

pp. 72-77 ◽

Cited By ~ 85

Author(s):

C. Manegold ◽

N. van Zandwijk ◽

A. Szczesna ◽

P. Zatloukal ◽

J.S.K. Au ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment ◽

Gemcitabine And Cisplatin

Download Full-text

Sequential Versus Alternating Administration of Cisplatin/Etoposide and Topotecan as First-Line Treatment in Extensive-Stage Small-Cell Lung Cancer: Preliminary Results of a Phase III Trial of the Hellenic Oncology Research Group

Clinical Lung Cancer ◽

10.3816/clc.2005.n.034 ◽

2005 ◽

Vol 7 (3) ◽

pp. 183-189 ◽

Cited By ~ 8

Author(s):

Michail Ignatiadis ◽

Dimitris Mavroudis ◽

Marinos Veslemes ◽

John Boukovinas ◽

Kostas Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

Oncology Research ◽

Extensive Stage ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text